Bevacizumab and ranibizumab for neovascular age-related macular degeneration: A treatment approach based on individual patient needs

Canadian Journal of Ophthalmology

Volumn 47, Issue 2, 2012, Pages 165-169

  Bellerive, Claudine ^a   Cinq Mars, Benoît ^a   Lalonde, Gilles ^a   Malenfant, Mario ^a   Tourville, Éric ^a   Tardif, Yvon ^a   Giasson, Marcelle ^a   Hébert, Marc ^b  

^a LAVAL UNIVERSITY   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH CARE NEED; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPTICAL COHERENCE TOMOGRAPHY; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84862278946     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.01.011     Document Type: Article

References (26)

1. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-85.
2. Bressier NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1.
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-17.
4. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102: 1640-2. (Pubitemid 15204559)
5. Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Arch Ophthalmol. 2006;113:373-80.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. (Pubitemid 44511557)
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44. (Pubitemid 44511558)
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
9. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511. (Pubitemid 44620390)
10. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72.
11. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-90. (Pubitemid 44197628)
12. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:270-4. (Pubitemid 44318178)
13. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9. (Pubitemid 43946791)
14. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9. (Pubitemid 43946791)
15. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511. (Pubitemid 44620390)
16. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439-44. (Pubitemid 46624283)
17. Bakri SJ, Cameron JD, McCannel CA, et al. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 2006;142:162-4. (Pubitemid 43946808)
18. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26:512-8. (Pubitemid 44620391)
19. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-61. (Pubitemid 44318176)
20. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-9. (Pubitemid 44318177)
21. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-56.
22. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An Optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-83.
23. Anne FE, Geeta LA, Rosenfeld PJ, et al. An optical coherence tomography- guided, variable dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PRONTO Study. Am J Ophthalmol. 2007;143:566-83.
24. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009;116:1731-9.
25. Gupta OP, Shienbaum G, Patel A, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. ARVO 2009 Annual Meeting, Fort Lauderdale, Fla.
26. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364: 1897-908.